Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEO accession GSE267908 is currently private and is scheduled to be released on May 20, 2025.

ABSTRACT: GEO accession GSE267908 is currently private and is scheduled to be released on May 20, 2025.

PROVIDER: PRJNA1113620 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comparison of mesenchymal stromal cells derived from osteoarthritis and non-osteoarthritis patients

Project description:Osteoarthritis (OA) is a chronic, multifactorial disease of the joint, which involves synovial inflammation, bone remodeling, and cartilage destruction. It poses a serious burden of global disease, with an incidence rate that has increased by 9.3% between 1990 and 2017. In situ tissue engineering represents a strategy that takes advantage of physiological repair mechanisms and seeks to enhance them. A strong focus has been placed on mesenchymal stromal cells (MSCs) as a source for endogenous regeneration, as they have been shown to contribute to tissue recovery in OA. A potential senescent phenotype of OA MSCs could impose a major limitation on their regenerative potential. MSCs derived from the bone marrow of osteoarthritis and non-osteoarthritis patients were analyzed upon their expression of senescence markers using an affymetrix microarray to explore their suitability for an in situ tissue engineering approach.

2025-12-10 | GSE267908 | GEO

Comparison between articular chondrocytes and mesenchymal stromal cells for the production of articular chondrocyte implants

Project description:Focal lesions of articular cartilage give rise to pain and reduced joint function and may, if left untreated, lead to osteoarthritis. Implantation of in vitro generated, scaffold-free autologous cartilage discs may represent the best treatment option. Here we compare articular chondrocytes (ACs) and bone marrow-derived mesenchymal stromal cells (MSCs) for their ability to make scaffold-free cartilage discs.

2023-02-07 | PXD029434 | Pride

Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

Project description:Osteoarthritis (OA) is a chronic, multifactorial disease of the joint, which involves synovial inflammation, bone remodeling, and cartilage destruction. It poses a serious burden of global disease, with an incidence rate that has increased by 9.3% between 1990 and 2017. In situ tissue engineering represents a strategy that takes advantage of physiological repair mechanisms and seeks to enhance them. A strong focus has been placed on mesenchymal stromal cells (MSCs) as a source for endogenous regeneration, as they have been shown to contribute to tissue recovery in OA and other pathologies like myocardial infarction and injured liver or pancreas tissue. CCL25, also known as TECK, is a chemokine that has been prevsiously shown to recruit MSCs. We used a microarry analysis to elucidate the broader effect of the chemokine CCL25 on mesenchymal stromal cells derived from patients with osteoarthritis.

2025-12-10 | GSE267906 | GEO

Global Extracellular Vesicle Proteome Changes Across Time Upon Intraarticular Treatment of Mesenchymal Stromal Cells in an In Vivo model of Equine Osteoarthritis

Project description:Equine Osteoarthritis (OA) is a heterogeneous, degenerative disease of the musculoskeletal system with multifactorial causation, characterised by joint metabolic imbalance. Mesenchymal stromal cell therapy (MSC) is a form of regenerative medicine that utilises MSC properties to repair damaged tissues. MSCs have been described as acting via the paracrine signalling of secreted factors. Despite its wide use in veterinary clinical practices, the exact mechanism of action of MSCs has not been fully characterised. Here, we have characterised synovial fluid extracellular vesicles (EVs) from control, osteoarthritic and MSC treated animals in order to gain insights into this mechanism. An in vivo, carpal osteochondral fragment model of equine OA was used for this study. Six horses underwent surgical intervention. All horses enrolled in the study were female trotter horses between the ages of 4 and 7. The contralateral limb of each horse served as a sham control. 69 synovial fluid samples were collected via aseptic arthrocentesis at day 0, 18, 21, 28, 35, and 70. Allogenic mesenchymal stromal cell therapy from male donors was injected into the OA afflicted joint after day 18. Synovial fluid (200µl) was Hyalaronidase treated (1µg/ml) and EVs were isolated using differential ultracentrifugation. EVs were characterised in collaboration with Nanoview Biosciences, whereby the Exoview human tetraspanin assay was used. EV concentration, surface marker identification, fluorescent microscopy and tetraspanin colocalization analysis was performed using pooled samples reflecting experimental groups - control, OA and OA including MSCs - across time.

2023-03-11 | PXD035303 | Pride

Secretome Comparison of Mesenchymal Stromal Cells and Immature Osteoblasts

Project description:Osteoblasts are a key component of the endosteal hematopoietic stem cell (HSC) niche and have long been recognized with strong hematopoietic supporting activity. Osteoblast conditioned media (OCM) enhances the growth of hematopoietic progenitors in culture and modulate their engraftment activity. We aimed to characterize the hematopoietic supporting activity of OCM by comparing the secretome of immature osteoblasts to that of their precursor, mesenchymal stromal cells (MSC). Over 300 secreted proteins were quantified by mass spectroscopy in media conditioned with MSC or osteoblasts, with 47 being differentially expressed.

2020-07-17 | PXD017372 | Pride

Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

Project description:Expression data from human mesenchymal stromal cells from osteoarthritis donors treated with the chemokine CCL25

| PRJNA1113622 | ENA

Extracellular matrices of stromal cell subtypes regulate phenotype and contribute to the stromal microenvironment in vivo

Project description:Comparison of secreted proteins from heterogeneous mesenchymal stromal cells.

2024-05-29 | MSV000094888 | MassIVE

Secretome Comparison of Mesenchymal Stromal Cells and Immature Osteoblasts

2021-11-15 | MSV000088384 | MassIVE

Transcriptome comparison of cartilage from patients with and without osteoarthritis

Project description:Transcriptome comparison of cartilage from patients with and without osteoarthritis

| PRJNA483972 | ENA

Equine muscle-derived mesenchymal stem cells protect cartilage explants in osteoarthritis model: secretome characterization

Project description:Background: Osteoarthritis is a highly prevalent joint degenerative disease for which therapeutic treatments are limited or invasive. Cell therapy based on mesenchymal stem/stromal cells (MSCs) is therefore seen as a promising approach for this disease, in both human and horses. Objective: As the regenerative potential of MSCs is mainly conferred by paracrine function, the goal of this study is to characterize the secretome of muscle-derived MSCs (mdMSCs) in an in vitro model of OA to evaluate the clinical interest of mdMSCs as cell therapy for joint diseases like osteoarthritis. Methods: An equine osteoarthritis model composed of cartilage explants exposed to pro-inflammatory cytokines was first developed. Then, the effects of mdMSC coculture on cartilage explant were studied by measuring the glycosaminoglycan release and the NO2- production. To identify the underlying molecular actors, SILAC-based secretome analyses were conducted, in the presence of serum. The relative abundance of highly sequenced proteins was finally confirmed by western blot. Results: Co-culture with muscle-derived MSCs decreases the cytokine-induced glycosaminoglycan release by cartilage explants, suggesting a protecting effect of mdMSCs. Among the 52 equine proteins sequenced in the co-culture medium, the abundance of decorin and matrix metalloproteinase 3 was modified, as confirmed by western blot analyses. Conclusions: These results suggest that muscle-derived MSCs could reduce the catabolic effect of TNF and IL-1 on cartilage explant by decreasing the secretion and activity of Matrix Metalloproteinase 3 and increasing the decorin secretion

2022-11-08 | PXD031924 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data